Ginsenosides, potential TMPRSS2 inhibitors, a trade-off between the therapeutic combination for anti-PD-1 immunotherapy and the treatment of COVID-19 infection of LUAD patients
Mei Meng, Rui Gao, Zixue Liu and 6 more
Frontiers in Pharmacology · 2023
doi:10.3389/fphar.2023.1085509 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
References54
- 6.
- 12.
- 14.Corrected
- 17.
- 18.
- 29.
- 32.
- 33.
- 43.
- 46.
44 more references, whose wording the paper’s licence keeps private.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.